Literature DB >> 2910832

Immunosuppressive activity of human neuroblastoma tumor gangliosides.

G Floutsis1, L Ulsh, S Ladisch.   

Abstract

Gangliosides are shed in substantial amounts by some tumors, including human neuroblastoma, and these molecules modulate experimental tumor formation in vivo. We now demonstrate that neuroblastoma tumor gangliosides have potent immunoregulatory activity. Gangliosides of every one of 17 tumors studied were highly inhibitory for the normal in vitro human lymphoproliferative responses to the soluble antigen, tetanus toxoid; 30 nmol ganglioside/ml caused 43% to greater than 99% inhibition and the mean concentration causing 50% inhibition was only 17.3 nmol/ml. Furthermore, gangliosides isolated from clinically more aggressive tumors (Stage III or IV) were up to twice as immunosuppressive as those of the generally less aggressive tumors (Stage I or II) (p less than 0.05). Taken together with the lack of immunosuppressive activity of normal plasma gangliosides, the potent activity of neuroblastoma gangliosides supports the hypothesis that one mechanism by which these shed molecules may act to enhance tumor formation in vivo is through abrogation of the host cellular immune response at the site of tumor formation.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2910832     DOI: 10.1002/ijc.2910430103

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  16 in total

1.  Serum immunoassay of a small cell lung cancer associated ganglioside: development of a sensitive scintillation proximity assay.

Authors:  T Pallesen; A Vangsted; L Drivsholm; H Clausen; J Zeuthen; H Wallin
Journal:  Glycoconj J       Date:  1992-12       Impact factor: 2.916

2.  Structural characterization and in vivo immunosuppressive activity of neuroblastoma GD2.

Authors:  R Li; D Gage; R McKallip; S Ladisch
Journal:  Glycoconj J       Date:  1996-06       Impact factor: 2.916

Review 3.  Sphingolipids in neuroblastoma: their role in drug resistance mechanisms.

Authors:  Hannie Sietsma; Anne Jan Dijkhuis; Willem Kamps; Jan Willem Kok
Journal:  Neurochem Res       Date:  2002-08       Impact factor: 3.996

4.  Gangliosides inhibit the development from monocytes to dendritic cells.

Authors:  M Wölfl; W Y Batten; C Posovszky; H Bernhard; F Berthold
Journal:  Clin Exp Immunol       Date:  2002-12       Impact factor: 4.330

5.  1H NMR ganglioside ceramide resonance region on the differential diagnosis of low and high malignancy of brain gliomas.

Authors:  V Lombardi; L Valko; M Valko; A Scozzafava; H Morris; M Melnik; J Svitel; M Budesinský; J Pelnár; J Steno; T Liptaj; L Zalibera; J Budinská; J Zlatos; A Giuliani; L Mascolo; D Leibfritz; A Troncone; F Marzullo; M Mazur; J Klener; E Zverina
Journal:  Cell Mol Neurobiol       Date:  1997-10       Impact factor: 5.046

6.  Ganglioside synthase knockout in oncogene-transformed fibroblasts depletes gangliosides and impairs tumor growth.

Authors:  Y Liu; S Yan; A Wondimu; D Bob; M Weiss; K Sliwinski; J Villar; V Notario; M Sutherland; A M Colberg-Poley; S Ladisch
Journal:  Oncogene       Date:  2010-03-22       Impact factor: 9.867

7.  Ceramide structure predicts tumor ganglioside immunosuppressive activity.

Authors:  S Ladisch; R Li; E Olson
Journal:  Proc Natl Acad Sci U S A       Date:  1994-03-01       Impact factor: 11.205

Review 8.  Gene-modified dendritic cells for immunotherapy against cancer.

Authors:  Andreas Lundqvist; Pavel Pisa
Journal:  Med Oncol       Date:  2002       Impact factor: 3.064

9.  Gangliosides are potent immunosuppressors of IL-2-mediated T-cell proliferation in a low protein environment.

Authors:  P Lu; F J Sharom
Journal:  Immunology       Date:  1995-11       Impact factor: 7.397

10.  Human stomach carcinoma-specific T cells derived from the tumour-draining lymph nodes.

Authors:  K Stulle; H P Vollmers; P Marquardt; H K Müller-Hermelink
Journal:  Br J Cancer       Date:  1994-12       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.